Physician

Srilakshmi Rebala, M.D.

According to 2025 Medicare claims, Srilakshmi Rebala, M.D. (NPI: 1730173733) practices nephrology in the Athens-Clarke County, GA market, with the plurality of this provider's patient population coming from Clarke, GA. This provider's primary affiliated billing organization is GEORGIA RENAL ASSOCIATES, PC (NPI: 1780851436; TIN: 262197799) and primary practice location at 30606-2179. Rebala is affiliated with the Piedmont Clinic ACO LLC (ACO ID: A3250), participating under the MSSP model.

Rebala's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 836 traditional Medicare patients, billed 3,392 HCPCS/CPT codes, and received $317,657 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 2,265 prescription claims across 377 beneficiaries totaling $374,189 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 39 claims. Open Payments data shows 15 records totaling $147. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $461,090 and ending at $374,189. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,023	6,518	$456,688
2016	956	5,013	$401,925
2017	1,034	5,850	$512,236
2018	1,025	6,246	$590,637
2019	1,006	5,618	$534,239
2020	989	5,051	$528,649
2021	951	4,628	$562,229
2022	886	4,576	$498,777
2023	827	3,364	$382,896
2024	836	3,392	$317,657

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	375	3,478	$461,090
2016	358	2,216	$324,782
2017	375	2,310	$521,513
2018	410	2,292	$431,901
2019	325	2,131	$331,499
2020	348	2,224	$282,828
2021	396	2,036	$287,267
2022	393	2,167	$297,628
2023	352	2,137	$465,371
2024	377	2,265	$374,189

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	29	$692
2021	N/R	26	$2,627
2022	N/R	116	$4,622
2023	N/R	91	$2,692
2024	N/R	39	$734

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	144	144	$120
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	116	131	$98
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	553	940	$89
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	183	672	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	544	830	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	46	1,631	$137,375
Auryxia	Ferric Citrate	15	810	$36,056
Farxiga	Dapagliflozin Propanediol	46	2,160	$34,477
Sevelamer Carbonate	Sevelamer Carbonate	149	6,227	$20,947
Veltassa	Patiromer Calcium Sorbitex	12	529	$12,587

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$351
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	12	$195
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$188

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	15	$147	AKEBIA THERAPEUTICS INC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Srilakshmi Rebala, M.D.?

Tedicare shows public-source Medicare data for Srilakshmi Rebala, M.D. (NPI 1730173733), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Srilakshmi Rebala, M.D. have ACO affiliation data?

Srilakshmi Rebala, M.D. is shown with ACO affiliation data for Piedmont Clinic ACO LLC (MSSP, ACO ID A3250).

What billing organization is linked to Srilakshmi Rebala, M.D.?

Srilakshmi Rebala, M.D. is linked to GEORGIA RENAL ASSOCIATES, PC (billing NPI 1780851436) in the available physician profile data.

Does Srilakshmi Rebala, M.D. have Open Payments data?

Srilakshmi Rebala, M.D. has 15 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.